# US 2014/0194382 A1 · Boronic acid derivatives and therapeutic uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0194382 A1
- Document ID: US20140194382A1
- Status: Published application
- Kind: A1
- Application number: 13/829,687
- Filed: 2013-03-14
- Published: 2014-07-10
- Earliest claimed: 2013-01-04
- Assignees: Rempex Pharmaceuticals, Inc.
- Applicants: Rempex Pharmaceuticals, Inc.
- Inventors: Raja Reddy; Tomasz Glinka; Maxim Totrov; Scott Hecker
- Web page: https://patentgrep.com/patent/US20140194382A1

## CPC

- A61K 31/69: Boron compounds
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/546: containing further heterocyclic rings, e.g. cephalothin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/04: Antibacterial agents
- C07F 5/02: Boron compounds
- C07F 5/025: {Boronic and borinic acid compounds}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents.

## Claims

### Claim 1

A compound having the structure of formula I:
or pharmaceutically acceptable salt thereof, wherein:
G is selected from the group consisting of —H, —NR1R2, —CH2N3, —C(O)NR1R2, —CH2C(O)NR1R2, —CH2S(O)2NR1R2, —CH2—Y—X, and —SR3;
Y is selected from a group consisting of —S—, —S(O)—, —S(O)2—, —O—, and —NR1—;
R is selected from a group consisting of —H, —C1-9alkyl, —CR1R2OC(O)C1-9alkyl, —CR1R2OC(O)OC1-9alkyl, and
R1 and R2 are each independently selected from the group consisting of —H and —C1-4alkyl;
R3 is —C1-4alkyl;
R4 is present 1 to 3 times and each R4 is independently selected from the group consisting of —H, —C1-4alkyl, —OH, —O C1-4alkyl, and halogen;
Z is selected from the group consisting of aryl optionally substituted with C1-4alkyl, amino, hydroxy, or halogen and heteroaryl optionally substituted with C1-4alkyl, amino, hydroxy, or halogen;
X is selected from the group consisting of —C1-4alkyl, —CH2R5, —CH(R5)2, and —C(R5)3; and
R5 is selected from the group consisting of a halogen, cyano, and azido group.

### Claim 2 (depends on 1)

The compound of claim 1, having the structure of (Ia):
or pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R is H.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R4 is H.

### Claim 5 (depends on 1)

The compound of claim 1, wherein G is H.

### Claim 6 (depends on 1)

The compound of claim 1, wherein G is —NH2.

### Claim 7 (depends on 1)

The compound of claim 1, wherein G is —C(O)NR1R2 and R1 and R2 are each independently selected from —H and C1-4alkyl.

### Claim 8 (depends on 7)

The compound of claim 7, wherein R1 is —CH3 and R2 is —CH3.

### Claim 9 (depends on 1)

The compound of claim 1, wherein G is —CH2C(O)NR1R2 and R1 and R2 are each independently selected from —H and C1-4alkyl.

### Claim 10 (depends on 9)

The compound of claim 9, wherein R1 is —CH3 and R2 is —CH3.

### Claim 11 (depends on 1)

The compound of claim 1, wherein R3 is CH3.

### Claim 12 (depends on 1)

The compound of claim 1, wherein:
G is CH2-Y—Z;
Y is —S—; and
Z is selected from the group consisting of imidazole, N-methylimidazole, aminoimidazole, triazole, N-methyl triazole, aminotriazole, tetrazole, N-methyltetrazole, aminotetrazole, thiazole, aminothiazole, thiadiazole, aminothiadiazole, oxazole, oxadiazole, pyridine, pyridazine, pyrimidine and pyrazine.

### Claim 13 (depends on 12)

The compound of claim 12, wherein Z is N-methyltetrazole.

### Claim 14 (depends on 12)

The compound of claim 12, wherein Z is thiadiazole.

### Claim 15 (depends on 12)

The compound of claim 12, wherein Z is aminothiadiazole.

### Claim 16 (depends on 1)

The compound of claim 1, wherein:
G is —CH2-Y—X; and
Y is —S—.

### Claim 17 (depends on 16)

The compound of claim 16, wherein X is CH3.

### Claim 18 (depends on 16)

The compound of claim 16, wherein X is CH2CN.

### Claim 19 (depends on 16)

The compound of claim 16, wherein X is CH2N3.

### Claim 20 (depends on 16)

The compound of claim 16, wherein X is —CH2F.

### Claim 21 (depends on 16)

The compound of claim 16, wherein X is —CHF2.

### Claim 22 (depends on 16)

The compound of claim 16, wherein X is —CF3.

### Claim 23 (depends on 1)

The compound of claim 1, having the structure selected from the group consisting of:
or pharmaceutically acceptable salts thereof.

### Claim 24 (depends on 1)

The compound of claim 1, having the structure selected from the group consisting of
or pharmaceutically acceptable salts thereof.

### Claim 25

A compound having the structure of formula II:
or pharmaceutically acceptable salt thereof, wherein:
G is selected from the group consisting of

### Claim 26 (depends on 25)

The compound of claim 25, having the structure of:
or pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 25)

The compound of claim 25, having the structure selected from the group consisting of:
or pharmaceutically acceptable salt thereof.

### Claim 28 (depends on 25)

The compound of claim 25, having the structure selected from the group consisting of:

### Claim 29 (depends on 25)

The compound of claim 25, wherein G is selected from the group consisting of

### Claim 30 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable excipient.

### Claim 31 (depends on 30)

The pharmaceutical composition of claim 30, further comprising an additional medicament.

### Claim 32 (depends on 31)

The composition of claim 31, wherein the additional medicament is selected from an antibacterial agent, antifungal agent, an antiviral agent, an anti-inflammatory agent, or an anti-allergic agent.

### Claim 33 (depends on 32)

The composition of claim 32, wherein the additional medicament is a β-lactam antibacterial agent.

### Claim 34 (depends on 33)

The composition of claim 33, wherein the β-lactam is selected from Amoxicillin, Ampicillin (Pivampicillin, Hetacillin, Bacampicillin, Metampicillin, Talampicillin), Epicillin, Carbenicillin (Carindacillin), Ticarcillin, Temocillin, Azlocillin, Piperacillin, Mezlocillin, Mecillinam (Pivmecillinam), Sulbenicillin, Benzylpenicillin (G), Clometocillin, Benzathine benzylpenicillin, Procaine benzylpenicillin, Azidocillin, Penamecillin, Phenoxymethylpenicillin (V), Propicillin, Benzathine phenoxymethylpenicillin, Pheneticillin, Cloxacillin (Dicloxacillin, Flucloxacillin), Oxacillin, Meticillin, Nafcillin, Faropenem, Tomopenem, Razupenem, Cefazolin, Cefacetrile, Cefadroxil, Cefalexin, Cefaloglycin, Cefalonium, Cefaloridine, Cefalotin, Cefapirin, Cefatrizine, Cefazedone, Cefazaflur, Cefradine, Cefroxadine, Ceftezole, Cefaclor, Cefamandole, Cefminox, Cefonicid, Ceforanide, Cefotiam, Cefprozil, Cefbuperazone, Cefuroxime, Cefuzonam, Cefoxitin, Cefotetan, Cefmetazole, Loracarbef, Cefixime, Ceftriaxone, Cefcapene, Cefdaloxime, Cefdinir, Cefditoren, Cefetamet, Cefmenoxime, Cefodizime, Cefoperazone, Cefotaxime, Cefpimizole, Cefpiramide, Cefpodoxime, Cefsulodin, Cefteram, Ceftibuten, Ceftiolene, Ceftizoxime, Flomoxef, Latamoxef, Cefepime, Cefozopran, Cefpirome, Cefquinome, Ceftobiprole, Ceftaroline, CXA-101, RWJ-54428, MC-04,546, ME1036, Ceftiofur, Cefquinome, Cefovecin, RWJ-442831, RWJ-333441, or RWJ-333442.

### Claim 35 (depends on 33)

The composition of claim 33, wherein the β-lactam is selected from Ceftazidime, Biapenem, Doripenem, Ertapenem, Imipenem, Meropenem, or Panipenem.

### Claim 36 (depends on 33)

The composition of claim 33, wherein the β-lactam is selected from Aztreonam, Tigemonam, BAL30072, SYN 2416, or Carumonam.

### Claim 37 (depends on 1)

A method of treating or preventing a bacterial infection, comprising administering to a subject in need thereof, a compound according to claim 1.

### Claim 38 (depends on 37)

The method of claim 37, further comprising administering to the subject an additional medicament.

### Claim 39 (depends on 38)

The method of claim 38, wherein the additional medicament is selected from an antibacterial agent, antifungal agent, an antiviral agent, an anti-inflammatory agent, or an anti-allergic agent.

### Claim 40 (depends on 39)

The method of claim 39, wherein the additional medicament is a β-lactam antibacterial agent.

### Claim 41 (depends on 40)

The method of claim 40, wherein the β-lactam is selected from Amoxicillin, Ampicillin (Pivampicillin, Hetacillin, Bacampicillin, Metampicillin, Talampicillin), Epicillin, Carbenicillin (Carindacillin), Ticarcillin, Temocillin, Azlocillin, Piperacillin, Mezlocillin, Mecillinam (Pivmecillinam), Sulbenicillin, Benzylpenicillin (G), Clometocillin, Benzathine benzylpenicillin, Procaine benzylpenicillin, Azidocillin, Penamecillin, Phenoxymethylpenicillin (V), Propicillin, Benzathine phenoxymethylpenicillin, Pheneticillin, Cloxacillin (Dicloxacillin, Flucloxacillin), Oxacillin, Meticillin, Nafcillin, Faropenem, Tomopenem, Razupenem, Cefazolin, Cefacetrile, Cefadroxil, Cefalexin, Cefaloglycin, Cefalonium, Cefaloridine, Cefalotin, Cefapirin, Cefatrizine, Cefazedone, Cefazaflur, Cefradine, Cefroxadine, Ceftezole, Cefaclor, Cefamandole, Cefminox, Cefonicid, Ceforanide, Cefotiam, Cefprozil, Cefbuperazone, Cefuroxime, Cefuzonam, Cefoxitin, Cefotetan, Cefmetazole, Loracarbef, Cefixime, Ceftriaxone, Cefcapene, Cefdaloxime, Cefdinir, Cefditoren, Cefetamet, Cefmenoxime, Cefodizime, Cefoperazone, Cefotaxime, Cefpimizole, Cefpiramide, Cefpodoxime, Cefsulodin, Cefteram, Ceftibuten, Ceftiolene, Ceftizoxime, Flomoxef, Latamoxef, Cefepime, Cefozopran, Cefpirome, Cefquinome, Ceftobiprole, Ceftaroline, CXA-101, RWJ-54428, MC-04,546, ME1036, Ceftiofur, Cefquinome, Cefovecin, RWJ-442831, RWJ-333441, or RWJ-333442.

### Claim 42 (depends on 40)

The method of claim 40, wherein the β-lactam is selected from Ceftazidime, Biapenem, Doripenem, Ertapenem, Imipenem, Meropenem, or Panipenem.

### Claim 43 (depends on 40)

The method of claim 40, wherein the β-lactam is selected from Aztreonam, Tigemonam, BAL30072, SYN 2416, or Carumonam.

### Claim 44 (depends on 37)

The method of claim 37, wherein the subject is a mammal.

### Claim 45 (depends on 44)

The method of claim 44, wherein the mammal is a human.

### Claim 46 (depends on 37)

The method of claim 37, wherein the infection comprises a bacteria selected from Pseudomonas acidovorans, Pseudomonas alcaligenes, Pseudomonas putida, Burkholderia cepacia, Aeromonas hydrophilia, Francisella tularensis, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Providencia alcalifaciens, Providencia rettgeri, Providencia stuartii, Acinetobacter baumannii, Bordetella pertussis, Bordetella parapertussis, Bordetella bronchiseptica, Haemophilus ducreyi, Pasteurella multocida, Pasteurella haemolytica, Branhamella catarrhalis, Borrelia burgdorferi, Kingella, Gardnerella vaginalis, Bacteroides distasonis, Bacteroides 3452A homology group, Clostridium difficile, Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium leprae, Corynebacterium diphtheriae, Corynebacterium ulcerans, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus pyogenes, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus intermedius, Staphylococcus hyicus subsp. hyicus, Staphylococcus haemolyticus, Staphylococcus hominis, or Staphylococcus saccharolyticus.

### Claim 47 (depends on 37)

The method of claim 37, wherein the infection comprises a bacteria selected from Pseudomonas aeruginosa, Pseudomonas fluorescens, Stenotrophomonas maltophilia, Escherichia coli, Citrobacter freundii, Salmonella typhimurium, Salmonella typhi, Salmonella paratyphi, Salmonella enteritidis, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumoniae, Klebsiella oxytoca, Serratia marcescens, Acinetobacter calcoaceticus, Acinetobacter haemolyticus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Yersinia intermedia, Haemophilus influenzae, Haemophilus parainfluenzae, Haemophilus haemolyticus, Haemophilus parahaemolyticus, Helicobacter pylori, Campylobacter fetus, Campylobacter jejuni, Campylobacter coli, Vibrio cholerae, Vibrio parahaemolyticus, Legionella pneumophila, Listeria monocytogenes, Neisseria gonorrhoeae, Neisseria meningitidis, Moraxella, Bacteroides fragilis, Bacteroides vulgatus, Bacteroides ovalus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides eggerthii, or Bacteroides splanchnicus.
